[18F]F-AraG: Clinical Trials

5 trials of [18F]F-AraG, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1 completed, 1 recruiting, 1 terminated, 1 unknown. 2 Phase 1, 2 Phase 2, 1 Early Phase 1.

By phase and status

PhaseTrialsStatus
Phase 12Completed 1, Unknown 1
Phase 22Recruiting 1, Terminated 1
Early Phase 11Withdrawn 1

Follow [18F]F-AraG: new trials by email Literature Review of [18F]F-AraG trials Research Report on [18F]F-AraG

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Imaging Advanced NSCLC Patients Undergoing PD-1/PD-L1 Directed Therapy Using [18F]-FARAG
[18F]F-AraG - Advanced Non Small Cell Lung Cancer
Phase 2RecruitingCellSight Technologies, Inc.202023-11-012024-10-24
A Study Using [18F]F AraG PET to Evaluate Response to Checkpoint Inhibitor Therapy(CkIT) in Patients With Solid Tumors
[18F]F-AraG - Correlate Tracer Uptake to TCell Tumor Infiltration & CkIT Benefit
Phase 2TerminatedCellSight Technologies, Inc.92022-03-012026-03-27
[18F]-AraG for the Detection of T-Cell Activation in Advanced Non-small Cell Lung Cancer Patients Undergoing PD-1/PD-L1-Directed Therapy
Fluorine F 18 Ara-G - Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma
Early Phase 1WithdrawnUniversity of California, Davis2019-11-052022-02-01
[18F]FAraG PET Imaging for Analysis of Biodistribution in Cancer Patients Expected to Undergo Immunotherapy and/or Radiation Therapy
[18F]F-AraG - Cancer
Phase 1UnknownCellSight Technologies, Inc.302017-05-012022-12-05
Study of Kinetics, Dosimetry & Safety of [18F]F-AraG, a Positron Emission Tomography Imaging Tracer in Healthy Humans
[18F]F-AraG - Cancer
Phase 1CompletedCellSight Technologies, Inc.62015-02-012018-05-17

Conditions studied

Neoplasms (2)  ·  Carcinoma, Non-Small-Cell Lung (1)  ·  Lung Neoplasms (1)

Sponsors

CellSight Technologies, Inc. (4)  ·  University of California, Davis (1)

Countries

United States (4)

Top investigators

Carina Mari Aparici, M.D. (1)  ·  Erik Mittra, M.D. (1)  ·  Henry VanBrocklin, Ph.D. (1)  ·  Julie Sutcliffe (1)  ·  Muhammad Furqan, M.D. (1)  ·  Robert R Flavell, M.D., Ph.D. (1)  ·  Shivaani Kummar, M.D. (1)

Results publications

PMID 20838911

NIH funding

P30CA093373 (1)